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INTERAKSI SISTEM SARAF SIMPATETIK DAN SISTEM RENIN 
ANGIOTENSIN PADA PEREDARAN DARAH SISTEMIK DI MODEL 
TIKUS HIPERTROFIK JANTUNG BERSAMA EKSPRESI Gα PROTEIN 
 
ABSTRAK 
Penyelidikan ini mengkaji kaitan di antara sistem saraf simpatetik (SNS) dan sistem 
renin angiotensin (RAS) di dalam hipertrofi jantung. Kajian hemodinamik dilakukan 
untuk menilai respon vasokonstriksi adrenoseptor (iaitu adrenoseptor α1 dan β1) dan 
reseptor angiotensin II jenis 1 (AT1) untuk memahami peranan fungsi SNS dan RAS 
dengan menggunakan model tikus hipertrofi jantung. Selanjutnya, penyelidikan 
ekspresi mRNA protein Gα melalui real-time PCR (RT-PCR) juga dilakukan untuk 
menilai beberapa isotype daripada 3 kumpulan protein Gα yang berbeza iaitu protein 
Gαs, Gαi dan Gαq/11 pada jantung tikus. Tikus WKY digunakan dan induksi hipertrofi 
jantung dilaksanakan dengan 2 dos isoproterenol (5 mg/kg) secara subkutenius dan 
dengan 40 mg/kg kafein di dalam larutan 1% sebanyak dua kali sehari secara oral 
selama 7 hari. Selain itu, blocker iaitu atenolol, doxazosin dan losartan juga 
diberikan, untuk menyiasat ciri antagonis ubat-ubat ini dalam menyekat reseptor 
tersebut, untuk melihat reaksi reseptor dan mentafsirkan ekspresi protein Gα. 
Peningkatan yang signifikan pada indeks jantung kepada tubuh dan garis dasar MAP 
pada tikus hipertrofi jantung berbanding dengan tikus WKY menunjukkan 
pengaktifan simpatetik. Selain itu, penilaian histologi pada jantung mengesahkan 
pembentukan hipertrofi jantung di dalam model tikus. Pengurangan fungsi 
adrenoseptor α1 pada tikus hipertrofi jantung, mencadangkan rangsangan berlawanan 
untuk merendahkan SNS yang semakin meningkat yang disebabkan oleh 
peningkatan fungsi adrenoseptors β1. Peningkatan fungsi adrenoseptors β1 ini 
disokong oleh pemerhatian terhadap amplifikasi ekspresi mRNA protein Gαs45 di 
dalam jantung hipertrofi. Tampaknya terdapat kaitan di antara kedua-dua 
 xxi 
 
adrenoseptor di dalam pengaturan  SNS dimana adrenoseptors α1 boleh menyekat 
stimulasi adrenoseptors β1 namun begitu, adrenoseptors β1 tidak mempunyai sebarang 
kesan terhadap stimulasi adrenoseptors α1. Fenomena ini juga diamati dalam 
hubungan di antara SNS dan RAS dimana reseptor AT1 berperanan mempengaruhi 
pengaktifan adrenoseptors α1 tetapi interaksi ini tidak berfungsi sebaliknya. 
Penyelidikan ini juga menunjukkan interaksi lain yang menghubungkan RAS dan 
SNS iaitu interaksi langsung di antara reseptor AT1 dengan adrenoseptor β1. Fungsi 
reseptor AT1 dan interaksi dengan adrenoseptor α1 dan β1  di dapati dimodulasi oleh 
kedua-dua protein Gαq dan Gα11 di dalam keadaan fisiologi normal mahupun  
jantung hipertrofi. Namun yang demikian, interaksi di antara adrenoseptor dengan 
protein Gαq/11 di dalam jantung berbeza di mana protein Gαq berkait rapat dengan 
stimulasi adrenoseptors β1 sedangkan protein Gα11 lebih berkaitan dengan stimulasi 
adrenoseptors α1. Perbezaan di antara subtype protein Gαs45 dan Gαs52 juga dicatat 
untuk pengesahkan penglibatan adrenoseptors β1 di dalam keadaan patofisiologi dan 
fisiologi. Sebagai kesimpulan, data-data ini mempunyai maklumat yang berharga 
mengenai hubungan di antara SNS dan RAS di  dalam keadaan hipertrofi jantung 
pada tahap reseptor dan juga pada tahap protein Gα di mana beberapa kes 
menunjukkan yang protein Gα yang berbeza subtype boleh bertindak berlainan 
walaupun termasuk di dalam kumpulan yang sama. 
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INTERACTION OF SYMPATHETIC NERVOUS SYSTEM AND RENIN 
ANGIOTENSIN SYSTEM IN SYSTEMIC CIRCULATION OF CARDIAC 
HYPERTROPHIC RAT MODEL WITH Gα PROTEIN EXPRESSION 
INTERFACE 
 
ABSTRACT 
The present study investigates the interrelation between sympathetic nervous system 
(SNS) and renin angiotensin system (RAS) in cardiac hypertrophy. Haemodynamic 
studies were performed to evaluate the vasoconstriction responses of adrenoceptors  
(i.e. α1- and β1- adrenoceptors) and angiotensin II type 1 receptors (AT1) to 
understand the functional role of SNS and RAS respectively using the cardiac 
hypertrophic rat model. Furthermore, the mRNA expression studies of Gα proteins 
via real time-PCR (RT-PCR) were also conducted to assess 2 isotypes from 3 
different groups of Gα proteins which are Gαs, Gαi and Gαq/11 proteins in the rat’s 
heart. WKY rats were used and cardiac hypertrophy was induced subcutaneously 
with 2 doses of isoproterenol (5 mg/kg) and 40 mg/kg of caffeine twice daily by 
gavage as 1% solution for 7 days. In addition, blockers namely atenolol, doxazosin 
and losartan were administered to investigate the antagonistic features of the 
respective drugs in blocking the intended receptors, in order to contemplate the 
receptors reaction and interpret the expression of Gα protein. Significant increments 
in the mean heart to body index and MAP baseline values were observed in cardiac 
hypertrophic rats compared to the WKY rats which depicted sympathetic activation. 
Moreover, histological evaluation of the heart sections confirmed cardiac 
hypertrophy in the rat model. Reduced functionality of α1- adrenoceptors in cardiac 
hypertrophic rats was suggested to counteract persistent SNS stimulation caused by 
the increased functionality of β1-adrenoceptors which was made apparent by the 
Gαs45 mRNA expression amplification in the hypertrophic heart. It appears that 
 xxiii 
 
crosstalk exists between both adrenoceptors in SNS regulation whereby α1-
adrenoceptors could interrupt β1-adrenoceptors stimulation, however, β1-
adrenoceptors does not exert any effect on α1-adrenoceptors. This phenomenon was 
also observed in a connection between SNS and RAS whereby AT1 receptors 
functional role may influence α1- adrenoceptors activation but the interaction does 
not work the other way round. Another support of the correlation linking SNS and 
RAS was also shown in the direct interaction of AT1 receptors and β1-adrenoceptors. 
The functionality of AT1 receptors and its interaction with α1- and β1- adrenoceptors 
were observed to be modulated by both Gαq and Gα11 protein mediated pathway in 
cardiac hypertrophic and physiological states. Nevertheless, the interaction between 
adrenoceptors with Gαq/11 protein in normal heart differs as Gαq protein may have 
interrelated effect with β1-adrenoceptors signalling while Gα11 protein may acquire 
control over α1-adrenoceptors activation. Discrepancies amongst the Gαs45 and Gαs52 
protein subtype were also noted in confirming β1-adrenoceptors participation under 
pathophysiological and physiological condition. In conclusion, the data provide 
valuable information regarding the crosstalks between SNS and RAS in cardiac 
hypertrophic condition at the level of receptors and Gα protein interface where in 
some cases the different subtypes of Gα protein may act differently despite 
belonging to the same group. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Introductory to Cardiovascular Physiology  
1.1.1 The Number One Killer 
Heart failure is an alarming non communicable disease associated with a 
dynamic myocardial dysfunction and with poor clinical outcome (El-Demerdash et 
al., 2005). This idiopathic disease is a common clinical problem resulting in 
significant morbidity and mortality around the world. It has become the number one 
killer across the globe. Statistics from The World Health Organization 
(http://www.who.int/en/) estimated that 17 million people died from cardiovascular 
diseases every year, a staggering 30% of all global deaths.  
 For the past decade, cardiovascular diseases have claimed 25% death in 
Malaysia and it is a fatal epidemic that tops the chart of all causes of death in this 
country and also other developing countries. Through statistical collection, it was 
shown that acute coronory disease has no race boundaries and the prevalence is close 
to active smoking habit (Chin et al., 2008). 
Heart disease causes numerous complications and implications not only to the 
patients, but it also extends to the community and the nation as a whole. For the past 
decades, a considerable attention has been put into the health system of assessment 
and management of heart diseases (Thomas, 2007). Furthermore, multitudes of 
experimental and clinical studies have been done to comprehend the physiology and 
pathtophysiology of the heart. Each attempt has brought closer in understanding and 
appreciating the physiological aspect of cardiovascular system towards improving 
the mortality and morbidity of heart diseases.   
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1.1.2 Heart Anatomy 
The heart is a muscular pump responsible for pumping blood through the 
blood vessels by repeated, rhythmic contractions, which provide the necessary force 
to circulate the blood to all the tissues in the body (Applegate, 2000). The kardia, 
similar to the word cardiac came from ancient Greek which refers to the heart (Opie, 
2004). Basically, the heart contains four chambers namely of the right atrium, right 
ventricle, left atrium and left ventricle. The heart wall is made up of three layers of 
tissues, i.e. an outer layer epicardium, a middle myocadium and the internal 
endocardium layer (van Wijk et al., 2009).   
The heart provides tissues with continuous supply of oxygen and nutrients 
while removing metabolic waste products from them. Its function is modulated into 
circulatory system that can be broken down to  the systemic circulation, pulmonary 
circulation and coronary circulation (Applegate, 2000)(Figure 1.1).  
The circulations that institute the pathway of the blood through the heart is 
altogether a continuous flow and we need to apprehend that both of the atrias and 
ventricles contract at the same time. However, for the ease of understanding, 
attempts to explain the right heart blood route first, then the left may be applied 
(Applegate, 2000).   
The right atrium receives blood relatively low in oxygen and high in carbon 
dioxide venous return via the superior vena cava and inferior vena cava. The right 
atrium also receives blood from the coronory sinus of the coronary circulation, the 
circulation that provides the heart muscle itself with sufficient supply of oxygen and 
nutrients. The deoxygenated blood then flow through the tricuspid valve to fill the 
right ventricle during diastole phase.  
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Figure 1.1 Systemic and pulmonary circulation of the heart. The circulation of 
the blood from right atrium to right ventricle; from the right ventricle through 
passage of the lung into the left atrium, then to the left ventricle and aorta; to the 
vascular beds by way of the arteries past the tissues into the veins; eventually back to 
the base of the heart. RA, right atrium; RV, right ventricle; PA, pulmonary artery; 
LA, left atrium; LV, left ventricle; Ao, aorta; O2, oxygen. The faded dotted areas 
represent deoxygenated blood (Adapted from Opie, 2004). 
 
Subsequently the right ventricle contracts and propels the venous return 
through the pulmonary semilunar valve and to the pulmonary vascular tree where it 
gets oxygenated in the capillaries of the lungs. This part of explanation belongs to the 
pulmonary circulation by which the systolic pressure generated by the right ventricle 
is much less then the left, as it only requires pushing the blood to the lungs. In 
addition, the right side of the heart is made out of thinner walled muscular chambers, 
corresponding to the lesser force it needs compared to the left side of the heart 
(Burkhoff et al., 1984). 
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Applying to the same analogy as the pulmonary circulation, the systemic 
circulation begins by the oxygenated blood from the lungs entering the left atrium 
and during the diastole period, the bicuspid valve opens and allows the blood to the 
left ventricle. Then, throughout the systole phase, the thick wall of left ventricle 
contracts building a reasonable huge force that abruptly closes the bicuspid valve and 
forces the opening of aortic valve, sending the blood to the whole body (Applegate, 
2000).   
 
1.1.3 Conduction System  
The heart beat and contraction of the four chambers are coordinated and 
initiated by a wave of electricity that arises voluntarily by specialized cells which are 
the main players of the heart conduction system. The sinoatrial (SA) nodes, situated 
at the posterior wall of the right atrium, commonly initiates the electrical impulses 
for contraction. The impulses spread rapidly through the left and right atria and reach 
to the atriaventricular (AV) node, which is located beneath the right atrium and close 
to the interatrial septum. There is a brief delay of impulse travelling in this node, 
giving time for the atrium to finish their contraction before the ventricle starts 
contracting. Then, the impulses accelerate to the bundle of His and consequently to 
the right and left bundles branches which extend to form Purkinje fibers that 
distribute the impulses throughout the ventricles to produce ventricle contraction 
(Applegate, 2000; Opie, 2004; Lily, 2007). 
 
1.1.4 Arterial Blood Pressure and Haemodynamic Factors 
During the left ventricle contraction, blood is propeled into the aorta which 
divides into many arteries and later smaller arteries known as arterioles before 
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reaching the capillaries. The arterial walls are thicker to withstand the pressure, 
compared to the subsequent vessels heading to the right atrium, known as the veins 
(Opie, 2004). 
Both the arteries and the veins possess the same three layers of intima, media 
and adventitia (Applegate, 2000). Not only is the composition of each layer between 
the arteries and veins different, there are also many crucial variances between the 
bigger vessels and the smaller ones (e.g. aorta and arteriole). This is to accommodate 
the sudden changes of pressure pattern throughout the circulation in different vessels, 
from high arterial pressure to low venous pressure (Parati et al., 1989).  
The aorta stretches during the high pressure of systole and recoil during the 
diastole in order to attune to the oscillating pressure from the left ventricle (Lily, 
2007). However, the high pressure is actually more prominent in the later arteries and 
arterioles where it provides resistance as the arterial lumen decreases. The arteries 
play an important role in regulating the blood flow and its velocity hence, controlling 
the arterial blood pressure or simply known as blood pressure (Opie, 2004). 
Blood pressure changes during exercise; responding to emotional status; and 
having a diurnal variation. The blood pressure from the brachial artery can easily be 
measured using the sphygmomanometer (Applegate, 2000). It is crucial to monitor 
the blood pressure because it is an accredit to the hemodynamic factors which 
impose to cardiac output (CO) and peripheral resistance (PR) that also affect other 
attributes such as stroke volume (SV) and heart rate (HR). On that account, blood 
pressure could mirror the well-being of the cardiovascular system. Notably, the 
progressive and linear increase of blood pressure can predispose a person to 
hypertension which more often than not, leads to alarming cardiovascular 
complications (Lily, 2007). 
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The relations between these hemodynamic factors are depicted from the 
formulae below. 
BP = CO x TPR 
CO = HR x SV 
Blood pressure (BP) is influenced by ways of cardiac output (CO) and total 
peripheral resistance (TPR).  In other equation, CO is proportional to the effect of 
heart rate (HR) and stroke volume (SV). CO (ml/min) is the blood volume ejected 
from the ventricle per minute, whereas SV (ml/cycle) is the blood volume out from 
the ventricle per contraction (Applegate, 2000). 
SV is dependent on several factors namely preload (i.e. end-diastolic 
volume), venous return, cardiac contractility and cardiac strength (Applegate, 2000; 
Lily, 2007).  All these extrinsic factors contribute to the Starling law of the heart. 
Starling law explains that the cardiac muscle fibers stretches as the venous filling 
pressure increases and the extension of the heart  increases its force of contraction 
which in return augments the SV (Rang et al., 2003). The Starling law also proposes 
about the longitudinal fibrils of cardiac muscles which refers to the cross bridge 
interaction and also give a view on the intrinsic factors of the heart itself which refer 
to the aberrant molecular active compound of heart failure that imparts to the modern 
view of calcium cycle abnormalities in heart failure (Dauterman et al., 1995). 
All these hemodynamic factors that apply to the heart, blood vessels and the 
circulation of the cardiovascular system are constantly under the regulation of several 
signals that change to accommodate the homeostasis of the body. Signals from the 
autonomic nervous system, renin angiotensin system, baroreflex central control,  and 
also from the vascular bed itself (e.g. nitric oxide signaling, endothelin) are very 
pivotal in modulating throughout the physiologic adjustment (e.g. during exercise or 
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rest) and most importantly during the challenges of pathologic alteration in 
cardiovascular system (Applegate, 2000; Opie, 2004; Lily, 2007).  
 
1.2  Autonomic Nervous System 
1.2.1  The Basic of Autonomic Nervous System 
The autonomic nervous system comprises of two distinguish systems 
which is the sympathetic (i.e. adrenergic) nervous system and parasympathetic (i.e 
cholinergic or vagal) nervous system (Alexander et al., 1994). Some would also like 
to include the enteric nervous system as one of the systems which consists of 
underlying neurons in the intramural plexuses of the gastrointestinal system (Rang et 
al., 2003).  
 Both the sympathetic and parasympathetic systems have their own fair share 
of duty where they work hand in hand and either can be more or less active 
depending on the particular requirement of the physiological state. The former 
predominates in states of excitation, for instance during emotional stress and 
exercise, whereas the latter predominates during satiation and repose. Each system 
conveys all their output from the central nervous system via two series of neurons 
(i.e. preganglionic and postganglionic) to the terminal nerve fibers which position 
proximate to the cells of the organ to be controlled (Rang et al., 2003). The synaptic 
bulb of the nerve ending releases neurotransmitters which travel through the synaptic 
junction that serves as messengers to evoke the actions of their corresponding 
neurons and eventually act upon the receptors on the specific cell membrane sites 
(Missler et al., 2003). 
 The neurotransmitters that serve the sympathetic nervous system are 
catecholamines, namely adrenaline and noradrenaline, while acetylcholine is the 
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neurotransmitter that attends to parasympathetic nervous system. Basically the 
adrenaline and noradrenaline act on adrenoreceptors which comprise of α 
adrenoceptors (α1 and α2) and β adrenoceptors (β1, β2 and β3). On the other hand 
acetylcholine acts on muscarinic (M1, M2, M3, M4 and M5) and nicotinic receptors. 
All these receptors are also known as G protein coupled receptors (GPCRs) (Rang et 
al., 2003).  
 In addition, there is also a regulatory neuronal activity called 
neuromodulation which influences the release of noradrenaline from the terminal 
neurons. Depending on the location, the neuromodulation process can be pre- or  
post-synaptic. It is known that mutual presynaptic inhibition can occur by which the 
release of noradrenaline from sympathethic nerve terminal can inhibit the release of 
acetylcholine, and acetylcholine can also act on noradrenaline the same way. This 
interaction is called heterotropic interaction, where one neurotransmitter affects the 
release of another. It can also be a homotropic interaction where the effect of one 
neurotransmitter is from the same neuron. This is particularly true for noradrenaline 
as it is known to inhibit its own release by acting on α2-adrenoceptors (Rang et al., 
2003; Opie, 2004; Brink et al., 2004). 
 
1.2.2 Sympathetic Nervous System 
The avenue of vasculature system is greatly authorized by the changes in the 
release of catecholamines from both the sympathetic nerves terminals and the adrenal 
medulla (Guimaraes and Moura, 2001).  
During excitatory state (e.g. dynamic exercise), the nerve ending of 
sympathetic nervous system (SNS) increases the release of noradrenaline to the sinus 
and atrioventricular node which causes sinus tachycardia and increases the rate of 
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conduction. This increases the heart rate and therefore brings positive chronotropic 
effects (Opie, 2004; Rang et al., 2003) (Figure 1.2). The release of noradrenaline also 
increases in the left ventricle and concurrently the adrenal medulla liberates 
adrenaline to all parts of the heart. Noradrenaline and adrenaline activate β1-
adrenoceptors in the heart, increasing intracellular cyclic 3’, 5’-adenosine 
monophosphate (cAMP) formation and hence intensifying inward Ca
2+
 current. As a 
result, the force of the heart contractility increases and gives rise to positive inotropic 
effect (Rang et al., 2003). 
 
 
 
Figure 1.2: Effects of SNS on heart circulatory system during dynamic exercise. 
The profound effect is the increase of cardiac output which brings about 
augmentation of preload (Starling mechanism) and inotropic activity. β-adrenergic 
stimulation (β) increases heart rate (HR) and inotropic state. α-adrenergic stimulation 
(α) contracts venous capacitance vessels to increase venous return (Adapted from 
Opie, 2004). 
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Although the effects of noradrenaline and adrenaline on the heart are 
compatible, their effects on the vasculature bed are conflicting. Adrenaline activates 
the β2-adrenoceptor on the arterioles which causes vasodilatation and thus increasing 
the limb’s blood flow. Due to the vasodilatation, the systolic BP augments even 
more; however, tending to decrease the diastolic BP. As a result, the increase of 
mean BP may not be as much. On the other hand, the noradrenaline is prone to act on 
arteriolar α1-adrenoceptors causing arterioles contraction and causing resistance to 
the heart work. In contrast to adrenaline, noradrenaline causes a rise in both the 
systolic and diastolic BP. In this condition where there is an excessive increase in 
BP, the baroreflexes will take over. The question is what are the net adrenergic 
effects on the vascular bed? The answer to this question remains obscure and 
complex. It was suggested that during muscle exertion activities, the adrenaline 
opposes the noradrenaline-mediated vasoconstrictive effects and the adrenaline-
mediated vasodilatory effects of β2-adrenoceptors prevail. However, it remains 
inconclusive as the general sympathetic stimulation on the arterioles varies from one 
individual to another. However, it is well documented that those who are 
hypertensive or prone to be hypertensive are likely to show vasoconstrictive effects 
(Opie, 2004). 
 
1.2.3 Parasympathetic Nervous System 
In parasympathetic activity, the muscarinic receptors respond to their 
messenger, acetylcholine and basically having an opposing effect to those of 
catecholamines. Principally, parasympathetic activation promotes cardiac slowing 
and inhibition of heart conductivity. The latter actualize seeing that the nodal tissue 
 11 
 
seems to be the main control of parasympathetic activity over the heart (Schauerte et 
al., 2001).  
This maybe due to the high occupancies of M2 receptors in this tissue, which 
contribute to the negative inotropic effect (Rang et al., 2003). The vagal effect on the 
heart muscle in decreasing the force of heart contractility is mostly of the atria rather 
than the ventricle, despite the similar densities of M2 receptors in these chambers. 
The responsiveness of ventricles towards acetylcholine may be less and there are 
probably some differences in downstream postreceptors actions (Opie, 2004).  
The M2 receptor activation reduces cAMP formation, which narrows down 
the β-adrenoceptors activation. Inhibiting sympathetic stimulation was also believed 
to be the main role of muscarinic receptors modulation, known as accentuated 
antagonism (Harvey and Belevych, 2003). Furthermore, nitric oxide (NO) may also 
assist in cholinergic stimulation by generating the second messenger, cyclic 3’,5’-
guanosine monophosphate (cGMP) that inhibits calcium channel opening and/or 
promoting the release of acetylcholine from vagal nerve ending (Massion et al., 
2003). 
The parasympathetic effect on the vascular bed is pretty straight forward 
where it stimulates overall vasodilatation. However, the main influence in 
vasodilatation effects on the arterioles is the local messengers, namely adenosine and 
nitric oxide. The former has a direct effect on the adenosine receptors on the vascular 
smooth muscle cells and a negative neuromodulatory effects by inhibiting the release 
of noradrenaline. The latter is a highly interactive free radical where it is synthesize 
in the vascular endothelium and the neuronal nitric oxide synthase (nNOS) is 
synthesized in the nitroxidergic nerves. In addition, it is also produce locally in the 
sinoatrial node to promote bradycardia effect (Opie, 2004).  
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1.2.4 Renin Angiotensin System 
The long term control of arterial blood pressure depends on the regulation of 
blood volume. This is where the renin angiotensin system (RAS) comes in 
responding to fluid and electrolyte (i.e. sodium) counterbalance. RAS imposes to 
encounter low renal perfusion, decreased in blood volume, a fall in BP or decreased 
in tubular reabsoption of sodium (Opie, 2004). During such events, renin is released 
from the kidneys which cleaves circulating angiotensinogen to angiotensin I in the 
liver. Then, the latter is rapidly split by angiotensin-converting enzyme (ACE) to 
form angiotensin II (Ang II), a powerful vasoconstrictor (Lily, 2007). Ang II is the 
chief executor peptide of RAS above other cognate peptides such as Ang 1-7, Ang III 
and Ang IV, which as well attracted much research interest on their effect towards 
cardiovascular function (Jones et al., 2008). 
Ang II acts on angiotensin II type 1 receptors (AT1) of arterial smooth muscle 
to cause vasoconstriction of the arterioles and therefore increasing TPR, which in 
turn regulates the systemic BP. In response to maintaining the intravascular volume, 
Ang II stimulates the release of aldosterone from the adrenal cortex that promotes 
sodium reabsorption in the kidney. Furthermore, Ang II also helps to release 
antidiuretic hormone that causes water retention, thus augmenting the intravascular 
volume, as well as acting on hypothalamus to enhance thirst and encourage water 
intake. In the heart, the Ang II evokes contractility and plays a chief role in the 
ventricular hypertrophy (Lily, 2007). 
Despite its compelling significance on the vascular/cardiac contractility and 
fluid/electrolyte balance, Ang II is also known to serve the role of autocrine and 
paracrine agent. Local synthesis of Ang II can manipulate cellular growth and 
regional haemodynamics of tissue in situ (Jones, 2008). 
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Additionally, RAS is also recognized to interact with other modulators such 
as those related to SNS where Ang II facilitates the release of noradrenaline. 
Likewise, bradykinin system too enhances noradrenaline released. However, having 
a different agenda that contradicts the RAS, the bradykinin production is 
counteracted by angiotensin converting enzyme (Cox et al., 2000). Moreover, RAS 
interacts with baroreflexes as well, attempting to offset the baroreflexes mediating 
bradycardia (Fabiani et al., 2001).  
Given all the benefits and crucial roles of the RAS in regulating BP, its 
effects in chronic disease state such as hypertension and heart failure could be 
decrementing (Opie, 2004). Studies through fetal, neonatal and adult cardiomyocytes 
have revealed many novel findings that implicate RAS as the culprit behind heart 
failure development (Schlüter et al., 2008). 
 
1.2.5 Baroreflexes 
Baroreflexes together with autonomic responses offer an acute regulation on 
the BP variation by detecting an increase or decrease in arterial pressure. The 
baroreceptors which are situated at the carotid sinus and aortic arch are a pressure 
sensitive cells that liberate their signals via glossopharyngeal and vagus nerves 
respectively. These signals are then carried to the vasomotor control in the brainstem 
where the signals evoke an effect on the sympathetic and parasympathetic nervous 
system. In a situation where an acute hypertension is detected, the baroreceptors 
stretch sending neuronal impulses to the vasomotor control which consequently 
inhibits sympathetic activities and in turn stimulate the parasympathetic activities. As 
a result, the TPR declines and reduction of heart rate and heart contractility become 
apparent, thus returning the BP to its basal level (Lily, 2007). 
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However, baroreflexes do not respond well to long term regulation of BP and 
therefore do not assist to counteract chronic hypertension. The reason for this is that 
the baroreceptors constantly reset themselves. After a day or two of exposure to 
higher than baseline pressures, the baroreceptor firing rate returns to its control value 
(Lily, 2007).  
 
1.3 G-Protein Coupled Receptors (GPCRs) 
1.3.1 Signal Transduction 
The vast GPCRs family represents many receptors from the autonomic 
nervous system. Adrenoceptors, muscurinic receptors, acethylcholine receptors, 
dopamine receptors and opiate receptors are all under the same family of GPCRs. 
GPCRs and their downstream effectors are often the subject of multitude research 
concerning cardiovascular system as it is vital to understand the physiological as well 
as the pharmacological perspective of these receptors (Wieland and Mittmann, 
2003). 
Through cloning, the molecular structures of GPCRs and their orphan 
receptors have been identified. All of them share a consistent architecture which is 
why there are collectively known as the seven transmembrane spanning  
(heptahelical) receptors with an extracellular N-terminal region of varying length and 
an intracellular C-terminal region (Rang et al., 2003). The latter region provides 
control interactions with other proteins that affect signal transduction GPCRs. The 
signal transduction of GPCRs begins from its activation by their corresponding 
neurotransmitter, and then coupled to their analogous G proteins before proceeding 
to the intracellular signal systems (Brink et al., 2004). 
 15 
 
There are three major types of intracellular signal systems that serve as the 
targets of G proteins. The first system, involve the activation of a membrane-bound 
enzyme known as adenylate cyclase. When activated, this membrane-bound enzyme 
produces the second messenger, cAMP from adenosine 5’-triphospate (ATP). 
Adenylate cyclase is the only exclusive enzyme system that is capable to yield 
cAMP. The series of cascade depends on the respective G protein that the GPCRs are 
coupled to. G protein is the determinant of whether the catalytic activity of adenylate 
cyclase is to be increased or decreased where it is equivalent to the production of 
cAMP within the cell. Consequently, cAMP activates protein kinases and 
commences the many regulation of cellular function (Rang et al., 2003 and Wheeler-
Jones, 2005).  
There are many agents that influence the formation of cAMP. The enzyme 
called phosphodiesterases inactivates cAMP by hydrolysis to adenosine 5’-
monophosphate (5’-AMP). Others such as β-adrenergic agonist, glucagon and 
forskolin stimulate cAMP production in the heart and consequently increase heart 
rate and contractility.   However, the increase of intracellular cAMP level in the heart 
may show different concentration in different cellular compartment in the heart. This 
cAMP compartmentation incident explains that even though, for example the 
forskolin or β-adrenergic agonist produce their effects by increasing the cAMP level, 
it does not mean that they will produce a uniform positive effect on the myocyte 
contractility. This phenomenon might act as a protective mechanism for the heart 
muscle from a harmful Ca
2+
 overload, amid to extensive term of cAMP activation 
(Georget et al., 2003). 
The second signal system is the phosphoinositide system. In this system, the 
activated receptors (e.g. α1-adrenoceptors, muscurinic receptors and angiotensin II 
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receptors) will couple to the appropriate G protein, where later triggers 
phospholipase C. Five phospholipase C (PLC) families have been identified as β 
(beta), γ (gamma), δ (delta), δ (zeta), and ε (epsilon). PLCβ, PLCγ and PLCε are well 
expressed in the cardiomyocyte and are suggested to interconnect with many cardiac 
signalling networks (Wang et al., 2005). 
The activation of phospholipase C results in the breakdown of its substrate 
identified as phosphatidylinositol 4,5-biphosphate (PIP2) to emanate two second 
messengers, diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3). Ultimately, 
the turnover of the system is restored as DAG is phosphorylated to form phosphatidic 
acid while the IP3 is dephosphorylated and recoupled with phosphatidic acid to form 
PIP2 once more (Rang et al., 2003). 
 IP3 is a hydrophilic mediator that stimulates the release of Ca
2+
 from the 
sarcoplasmic reticulum. DAG is highly lipophilic and exerts its effects through 
activation of protein kinase C (PKC), where it also results in the increase of Ca
2+
 
intracellular level. Together the IP3 and DAG being duo mediators elicit vascular 
contraction by raising cytosol calcium in the vascular smooth muscle (Kamp and 
Hell, 2000 and Opie, 2004).  
 With regard to cardiac function, the activation of phospholipase C may give 
either positive or negative inotropic effects (Opie, 2004). In heart failure, up 
regulation of phospholipase C might be an aid to compensate the β-adrenoceptor 
desensitization and down regulation, by promoting heart contractility. This situation 
can also exemplify the fact that communication exists between the adenylate cyclase 
system and phospholipase C system (Fan et al., 1998). 
However, the negative inotropic effect of phospholipase C, is not well 
documented and needs to be deduced further (Wang et al., 2005). Nonetheless, a 
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study proposed that there is a possibility that phospholipase C activation through α-
adrenoceptors’ transmission may depict Ca2+ dependence and resulting in negative 
inotropic effects (Capogrossi et al., 1991). 
The final G protein excitatory target is the ion channel, which denotes that G 
protein can directly interact with ion channels, either in an activating or inhibiting 
manner, without going through any second messengers (e.g. cAMP and 
phospholipase C). One good example that describes a direct interaction of G protein 
with ion channels would be the M2 receptors that regulate the activation of K
+
 
channels, enhancing the K
+
 permeability, hence, creating hyperpolarization in the 
cells. However, several studies have suggested that there is no exclusive pathway in 
which the ion channels are activated, proposing that both direct and indirect G 
protein-mediated receptors have their own justly way of modulating the ion channels. 
(Breitwieser, 1991). 
 
1.3.2  GPCRs Homodimerization and Heterodimerization 
The studies of GPCRs have evolved to another aspect. Rather than defining 
every single GPCRs as a single quantity, many researches are now looking at how 
these GPCRs physically interact with one another. A growing body of evidence 
indicates that GPCRs can form homodimers and heterodimers (Barnes, 2006). 
Homodimerization distinguishes from heterodimerization, where the former implies 
two identical GPCRs forming a complex, whereas the latter imply two different types 
of GPCRs forming a complex (Brink et al., 2004). This event of GPCRs has evolved 
several aspects and many agree that dimerization may be necessary for efficient 
agonist binding and signalling in physiological and pathophysiological state (Brink et 
al., 2004; Xiao et al., 2006). It has been investigated in culture cells that 
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adrenoceptors form dimers to facilitate receptor–ligand interactions in optimizing the 
signalling efficiency towards better cardiac contractility regulation and cardiac 
growth (Xiao et al., 2006). 
Moreover, receptors dimers may generate new drug binding sites and this can 
tremendously affect pharmacological approach of drug intervention. It has been 
shown that adenosine and dopaminergic receptors are able to form dimers, 
suggesting that future drug target for Parkinson's disease may be at adenosine 
receptors rather than at dopaminergic receptors (Brink et al., 2004). Nevertheless, 
further research is obligatory to fully appreciate this fascinating fine-tuning of 
GPCRs (Xiao et al., 2006). 
 
1.3.3 GPCR Sequestration 
 GPCRs are the first line recognition of extracellular stimuli (e.g. drugs and 
neurotransmitter) before any intracellular events could take place. However, through 
continuous or repeated activation, GPCRs could endure configurational changes that 
serve as a negative feedback to prevent excessive stimulation of a particular GPCR. 
(Lemaire and Rockman, 2004). There are many terms used to describe this 
phenomena, namely desensitization, downregulation and internalization. Although 
many researchers use these terms interchangeably, in fact each term defines and 
expresses different mechanism of the same end result, which is to inhibit further 
stimulation of any given GPCR. Thus GPCRs sequestration is presumed to be an act 
of compensatory feedback adapting to aberrant stimuli (Brink et al., 2004). 
When abide to desensitization, GPCRs are engulfed inwards into the 
membrane folding to form vesicles. These GPCR containing vesicles are freed into 
the cellular cytoplasm by a transaction called internalization resembles endocytosis. 
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Once internalized, the GPCR can either be metabolized by lysosomes (down-
regulation) or dephosphorylated (desensitization) and recycled to the cell membrane 
to replenish function (resensitization) (Brink et al., 2004). 
The features of desensitisation is referring to phosphorylation by serine and 
theonine kinases such as protein kinase A (PKA), protein kinase C (PKC) and 
specific membrane-bound GPCR kinases (GRKs). It can also occur as a heterologous 
desensitisation which is known as non-agonist specific desensitization, where the 
phosphorylation of one type of receptors is due to the activation of kinases by other 
receptors which share the same agonist (Lemaire and Rockman, 2004; Rang et al., 
2003; Freedman et al., 1995). 
Eminently, an agonist-specific desensitisation can also occur in a process 
known as homologous desensitisation which accounts for most GPCRs. In this case, 
phosphorylation is by GRKs and the phosphorylated receptors bind to inhibitory 
proteins, the β-arrestin isoforms that can result in blocked interaction with their 
respective G proteins. Basically the effect of homologous desensitisation is more 
intense and long lasting compared to the heterologous desensitisation which only 
offers the bases of seconds to minutes sequestration (Lemaire and Rockman, 2004). 
 
1.3.4 G proteins 
1.3.4.1 The Function of G protein and Subclasses 
Upon activation of GPCR, the responsible ligand either stabilizes or induces 
conformational changes in the receptor that activate one or many heterotrimeric G 
protein(s) on the inner membrane surface
 
of the cell. G proteins are a family of 
guanine triphosphate (GTP) - binding proteins, assigned as the middle man to 
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orchestrate the interaction between the GPCRs with the regulation of a variety signal 
transduction systems (Evi K et al., 2005).  
The heterotrimeric structure of G protein is an assembly of subunits 
characterized as α, β and γ. The α-subunit contains the helical domain that 
apprehends the GTP binding site known to be unique to each G protein. This helical 
domain uphold the specificity of receptor and distinct effector of every GPCR 
(Lefkowitz, 2004 and Itoh et al., 1988). During inactive state, the G protein exists as 
a trimeric structure whereby the βγ-dimers stays clinch to α-subunit, with  guanine 
diphosphate (GDP) occupying the site on the α-subunit (Rang et al., 2003 and 
Cabrera-Vera et al., 2003). 
The stoichiometry of G protein begins when a certain transmitter or agonist 
binds to the corresponding GPCR and triggers the configurational changes of 
intracellular domains of the receptor. These modifications require the receptor to 
associate with a number of G proteins. Activation of the GPCR promotes molecule 
exchange of GDP to GTP at the active site of α-subunit. This putative GDP/GTP 
exchange, in turn causes dissociation of the heterotrimeric complex, and releases the 
GTP-bound α-subunit and the βγ-dimer to interact with downstream intracellular or 
membrane effectors (Cabrera-Vera et al., 2003)( Figure 1.3). 
